CHP-105 is currently under investigation for the treatment of urinary tract infections. According to a pilot study, using a bacterial isolate responsible for a human clinical pyelonephritis case, the drug significantly reduces the bacteria count in the kidneys, bladder, and urine, added either intravenously, subcuteneously or orally.

Other urinary, gastrointestinal and respiratory tract infection models are being established and potential collaborators are being identified.